Abstract
Kit inhibitor monotherapy has moderated activity in melanoma harboring c-Kit aberrations (CKA) but with an unsatisfied objective response rate (ORR) of 23-26% and median progression free survival (mPFS) of 3.5-7.3mo. Thus we performed a phase II trial testing the imatinib mesylate/toripalimab (anti-PD-1 monoantibody) combo in pts with advanced melanoma harboring CKA. (NCT: 05274438).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
